Skip to main content
. 2021 Jan 29;11(1):e2021155. doi: 10.5826/dpc.1101a155

Figure 5.

Figure 5

Concomitant development of more than one skin toxicity is not unusual. The patient illustrated in (A) experienced vitiligo and psoriasis (see Figure 1B) and the patient in (B) experienced vitiligo and bullous pemphigoid, both during treatment with nivolumab for advanced melanoma.